Jonas from Norway

Registered at the short selling broker Capital, 2 minutes ago.

» Try Capital you too
67.7% of retail investor accounts lose money when trading CFDs with Capital.
Don't show again

Pfizer Inc. (PFE) shares information

Pfizer Inc.

24h Change

0.77 %


Live rate:

Stock data per Monday 8 Aug, 2022

0.38 (+ 0.77%)
US Market is open

Live Stock price in graph for Pfizer Inc. (PFE)

Data updated continously for PFE, showing up to the 500 most recent 100 data points

  • Latest Volume

    5,303,234 (-67.62 %)

  • Volume prev. day


  • Avg. daily volume


  • Market cap


  • P/E ratio


  • Today high

    49.81 USD

  • Today low

    48.94 USD

  • 52 week high

    60.28 USD

  • 52 week low

    39.64 USD

  • YTD Change


Quick links


Latest news about Pfizer Inc.

Below you can find the most recent news posts about Pfizer Inc., primarily from US and UK based news sources.

Pfizer to buy Global Blood Therapeutics in $5.4bn cash deal – Prompt News

Monday, 8 August 2022, 16:29:56
U.S. pharmaceutical maker Pfizer and Biopharmaceutical Company Global Blood Therapeutics (GBT) on Monday agreed that Pfizer will acquire GBT in an all-cash deal valued at 5.4 billion U.S. dollars. Pfizer said the acquisition would drive growth by enhancing its work in rare hematology while reinforcing the company’s commitment to sickle cell disease research and treatment.
— Prompt News Online

International Ekonomie: Pfizer keeft Global Blood Therapeutics fir 5,3 Milliarden Euro

Monday, 8 August 2022, 16:27:54
Den US-amerikanesche Pharmakonzern Pfizer ass domadder bereet, 68,50 US-Dollar pro Aktie an de Kaf vu Global Blood Therapeutics (GBT) z”investéieren.
— RTL Luxembourg

Oxbryta: Pfizer to acquire sickle cell drugmaker GBT for $5 bn

Monday, 8 August 2022, 16:21:50

— RTL Today

Pfizer to buy Global Blood Therapeutics

Monday, 8 August 2022, 15:52:20
Pfizer Inc. has agreed to buy Global Blood Therapeutics Inc., the maker of a drug for sickle-cell disease, in a deal worth $5.4 billion, Report informs via Bloomberg.
— Report AZ

Pfizer to Buy Global Blood Therapeutics

Monday, 8 August 2022, 15:48:00
Pfizer Inc (NYSE:PFE) is boosting its pipeline with a $5.4-billion deal for blood disorder drugmaker Global Blood Therapeutics (NASDAQ:GBT), the latest in a series of acquisitions to combat a potential slowdown in COVID-19 products demand as cases fall. Pfizer …
— Baystreet Canada

Trading broker recommendation

We recommend that you check out as they have a very good selection of stocks available for both going short and long.

Rating: 9.57/10
Minimum deposit: €250 by bank
Description: offer a large number of stocks for trading. Register an account today and check if they have PFE available or trade one of the many other CFD stocks they have.
Risk warning: 67.7% of retail investor accounts lose money when trading CFDs with Capital.